Donnan Jennifer, Ledger Séadna
Eastern Health, St. John's, Newfoundland.
CANNT J. 2006 Oct-Dec;16(4):32-6; quiz 37-8.
It is clear that the majority of the evidence for symptomatic management of DPN is for either TCAs or anticonvulsants. The Canadian Diabetes Association recommends agents from these classes as first-line therapy. Though these agents appear to be effective, the management of neuropathic pain is still quite difficult and many patients only achieve partial relief from therapy while others find no relief. It is important to focus on the prevention of onset and progression of diabetic neuropathy by dealing with the root of the problem, glycemic control. Patients should be educated on the importance of intensive glycemic control for the prevention of all diabetes complications, including peripheral neuropathy (Bril & Perkins, 2003).
显然,关于糖尿病性周围神经病变(DPN)症状管理的大多数证据都针对三环类抗抑郁药(TCAs)或抗惊厥药。加拿大糖尿病协会推荐这些类别的药物作为一线治疗。尽管这些药物似乎有效,但神经病理性疼痛的管理仍然相当困难,许多患者仅从治疗中获得部分缓解,而其他患者则没有缓解。通过解决问题的根源即血糖控制,专注于预防糖尿病性神经病变的发生和进展很重要。应该让患者了解强化血糖控制对预防所有糖尿病并发症(包括周围神经病变)的重要性(布里尔和珀金斯,2003年)。